# LNS8801

Source: https://onco.cc/drugs/lns8801/  
OnCo record `lns8801` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

LNS8801 is an experimental investigational agent whose form is not stated in the registry from Linnaeus Therapeutics in phase 3 trials for melanoma, aimed at Estrogen receptor (ERα).

## Summary

LNS8801 is an investigational agent whose form is not stated in the registry developed by Linnaeus Therapeutics. Its target is Estrogen receptor (ERα). ClinicalTrials.gov describes the intervention as: G protein-coupled estrogen receptor (GPER) agonist. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06624644 (A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma), in melanoma. The largest, NCT06624644, plans to enrol 135 participants with primary completion expected 2029-02. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: not stated (registered as a drug or biological on ClinicalTrials.gov)
- Mechanism: Investigational agent whose form is not stated in the registry directed at Estrogen receptor (ERα), as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

## Sources

- ClinicalTrials.gov: trials of LNS8801: https://clinicaltrials.gov/search?intr=LNS8801

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- targets: [Estrogen receptor (ERα)](https://onco.cc/targets/estrogen-receptor/)
- companies: [Linnaeus Therapeutics](https://onco.cc/companies/linnaeus-therapeutics/)
- trials: [A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma](https://onco.cc/trials/nct06624644/), [Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab](https://onco.cc/trials/nct04130516/)

---
JSON: https://onco.cc/api/v1/entities/lns8801.json